Newsletter 03
October 22 2008
Fall 2008
These are turbulent times, and although the financial crisis does not affect BioPorto’s business directly, it is nevertheless a situation that the company is following closely. In line with the rest of the stock market, BioPorto’s share price has also been affected by the latest developments. Internally, however, we are focusing on the ongoing NGAL licensing negotiations and other projects as described in the report for the second quarter of 2008.
This newsletter also reports on the latest investor meetings, NGAL patent issues and licensing negotiations, and takes a look at BioPorto’s MBL product as well as biomarkers in general.
